Ameliorative effect of N-desmethylclozapine in animal models of social deficits and cognitive functions

Brain Research Bulletin

Volumn 86, Issue 3-4, 2011, Pages 146-151

  Maehara, Shunsuke ^a,b   Okuda, Shoki ^a   Ohta, Hisashi ^a  

^a BANYU PHARMACEUTICAL CO LTD   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

M 1 muscarinic receptor; N desmethylclozapine; Object recognition; Schizophrenia; Social deficits

Indexed keywords

CLOZAPINE; DIZOCILPINE; NORCLOZAPINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; EXPLORATORY BEHAVIOR; LOCOMOTION; MALE; NONHUMAN; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RAT; RECOGNITION; SCHIZOPHRENIA; SOCIAL DISABILITY; SOCIAL INTERACTION;

ANIMALS; CLOZAPINE; COGNITION; DIZOCILPINE MALEATE; EXCITATORY AMINO ACID ANTAGONISTS; EXPLORATORY BEHAVIOR; INTERPERSONAL RELATIONS; MALE; MOTOR ACTIVITY; PSYCHOMOTOR PERFORMANCE; RATS; RATS, SPRAGUE-DAWLEY; RECOGNITION (PSYCHOLOGY); SCHIZOPHRENIC PSYCHOLOGY; SOCIAL BEHAVIOR;

EID: 80053265886     PISSN: 03619230     EISSN: 18732747     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2011.08.004     Document Type: Article

References (50)

1. Aleman A., Hijman R., de Haan E.H., Kahn R.S. Memory impairment in schizophrenia: a meta-analysis. Am. J. Psychiatry 1999, 156:1358-1366.
2. Anagnostaras S.G., Murphy G.G., Hamilton S.E., Mitchell S.L., Rahnama N.P., Nathanson N.M., Silva A.J. Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice. Nat. Neurosci. 2003, 6:51-58.
3. Aravagiri M., Marder S.R. Simultaneous determination of clozapine and its N-desmethyl and N-oxide metabolites in plasma by liquid chromatography/electrospray tandem mass spectrometry and its application to plasma level monitoring in schizophrenic patients. J. Pharm. Biomed. Anal. 2001, 26:301-311.
4. Baldessarini D.E., Frankenburg F.R. Clozapine a novel antipsychotic agent. N. Engl. J. Med. 1991, 324:746-754.
5. Baldessarini R.J., Centorrino F., Flood J.G., Volpicelli S.A., Huston-Lyons D., Cohen B.M. Tissue concentrations of clozapine and its metabolites in the rat. Neuropsychopharmacology 1993, 9:117-124.
6. Calkins M.E., Gur R.C., Ragland J.D., Gur R.E. Face recognition memory deficits and visual object memory performance in patients with schizophrenia and their relatives. Am. J. Psychiatry 2005, 162:1963-1966.
7. Didriksen M., Kreilgaard M., Arnt J. Sertindole, in contrast to clozapine and olanzapine, does not disrupt water maze performance after acute or chronic treatment. Eur. J. Pharmacol. 2006, 542:108-115.
8. Ennaceur A., Delacour J. A new one-trial test for neurobiological studies of memory in rats. I: behavioral data. Behav. Brain Res. 1988, 31:47-59.
9. Ennaceur A., Cavoy A., Costa J.C., Delacour J. A new one-trial test for neurobiological studies of memory in rats. II: effects of piracetam and pramiracetam. Behav. Brain Res. 1989, 33:197-207.
10. Ertuĝrul A., Özdemir H., Vural A., Dalkara T., Meltzer H.Y., Saka E. The influence of N-desmethylclozapine and clozapine on recognition memory and BDNF expression in hippocampus. Brain Res. Bull. 2011, 84:144-150.
11. Gerlach J., Peacock L. Motor and mental side-effects of clozapine. J. Clin. Psychiatry 1994, 55:107-109.
12. Guitton C., Kinowski J.M., Gomeni R., Bressolle F. A kinetic model for simultaneous fit of clozapine and norclozapine concentrations in chronic schizophrenic patients during long-term treatment. Clin. Drug Invest. 1998, 16:35-43.
13. Hou Y., Wu C.F., Yang J.Y., Guo T. Differential effects of haloperidol, clozapine and olanzapine on learning and memory functions in mice. Prog. Neuropsychopharmacol. Biol. Psychiatry 2006, 30:1486-1495.
14. Karasawa J., Hashimoto K., Chaki S. d-Serine and a glycine transporter inhibitor improve MK-801-induced cognitive deficits in a novel object recognition test in rats. Behav. Brain Res. 2008, 186:78-83.
15. 2A antagonist with a favorable CNS safety profile. J. Pharmacol. Exp. Ther. 1996, 277:968-981.
16. 1C receptor antagonists. Eur. J. Pharmacol. 1993, 245:179-182.
17. Maehara S., Satow A., Hikichi H., Ohta H. Antipsychotic effects of N-desmethylclozapine on sensorimotor gating function in rats-possible involvement of activation of M1 muscarinic receptors. Eur. J. Pharmacol. 2011, 667:242-249.
18. Marino M.J., Rouse S.T., Levey A.I., Potter L.T., Conn P.J. Activation of the genetically defined m1 muscarinic receptor potentiates N-methyl-d-aspartate (NMDA) receptor currents in hippocampal pyramidal cells. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:11465-11470.
19. Meltzer H.Y. Treatment-resistant schizophrenia-the role of clozapine. Curr. Med. Res. Opin. 1997, 14:1-20.
20. Meltzer H.Y., McGurk S.R. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr. Bull. 1999, 25:233-255.
21. 2A) in the consolidation of learning. Behav. Brain Res. 1997, 89:217-223.
22. Meyerson B.J., Höglund A.U. Exploratory and socio-sexual behavior in the male laboratory rat: a methodological approach for the investigation of drug action. Acta. Pharmacol. Toxicol. (Copenhagen) 1981, 48:168-180.
23. Morimoto T., Hashimoto K., Yasumatsu H., Tanaka H., Fujimura M., Kuriyama M., Kimura K., Takehara S., Yamagami K. Neuropharmacological profile of a novel potential atypical antipsychotic drug Y-931 (8-fluoro-12-(4-methylpiperazin-1-yl)-6H-[1]benzothieno[2 3-b][1,5] benzodiazepine maleate). Neuropsychopharmacology 2002, 26:456-467.
24. Mortimer A.M. Cognitive function in schizophrenia-Do neuroleptics make a difference?. Pharmacol. Biochem. Behav. 1997, 56:789-795.
25. Mostafa R.M., Mostafa Y.M., Ennaceur A. Effects of exposure to extremely low-frequency magnetic field of 2G intensity on memory and corticosterone level in rats. Physiol. Behav. 2002, 76:589-595.
26. Murray E.A., Richmond B.J. Role of perirhinal cortex in object perception, memory, and associations. Curr. Opin. Neurobiol. 2001, 11:188-193.
27. Okuda S., Roozendaal B., McGaugh J.L. Glucocorticoid effects on object recognition memory require training-associated emotional arousal. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:853-858.
28. Owen A.M., Downes J.J., Sahakian B.J., Polkey C.E., Robbins T.W. Planning and spatial working memory following frontal lobe lesions in man. Neuropsychologia 1990, 28:1021-1034.
29. Park S., Holzman P.S. Schizophrenics show spatial working memory deficits. Arch. Gen. Psychiatry 1992, 49:975-982.
30. 3 receptor antagonists reverse delay-dependent deficits in novel object discrimination by enhancing retrieval. Psychopharmacology 2009, 202:141-152.
31. Qiao H., Noda Y., Kamei H., Nagai T., Furukawa H., Miura H., Kayukawa Y., Ohta T., Nabeshima T. Clozapine, but not haloperidol, reverses social behavior deficit in mice during withdrawal from chronic phencyclidine treatment. Neuroreport 2001, 12:11-15.
32. Rosengarten H., Quartermain D. The effect of chronic treatment with typical and atypical antipsychotics on working memory and jaw movements in three- and eighteen-month-old rats. Prog. Neuropsychopharmacol. Biol. Psychiatry 2002, 26:1047-1054.
33. Safferman A., Lieberman J., Kane J. Update on clinical efficacy and side-effects of clozapine. Schizophr. Bull. 1991, 17:247-262.
34. Sams-Dodd F. Phencyclidine-induced stereotyped behavior and social isolation in rats: a possible animal model of schizophrenia. Behav. Pharmacol. 1996, 7:3-23.
35. Sams-Dodd F. Effect of novel antipsychotic drugs on phencyclidine-induced stereotyped behavior and social isolation in the rat social interaction test. Behav. Pharmacol. 1997, 8:196-215.
36. Sams-Dodd F. A test of the predictive validity of animal models of schizophrenia based on phencyclidine and d-amphetamine. Neuropsychopharmacology 1998, 18:293-304.
37. Satow A., Suzuki G., Maehara S., Hikichi H., Murai T., Murai T., Kawagoe-Takaki H., Hata M., Ito S., Ozaki S., Kawamoto H., Ohta H. Unique antipsychotic activities of the selective metabotropic glutamate receptor 1 allosteric antagonist 2-cyclopropyl-5-[1-(2-fluoro-3-pyridinyl)-5-methyl-1H-1 2,3-triazol-4-yl]-2,3-dihydro-1H-isoindol-1-one. J. Pharmacol. Exp. Ther. 2009, 330:179-190.
38. Sawaguchi T., Goldman-Rakic P.S. D1 dopamine receptors in prefrontal cortex: involvement in working memory. Science 1991, 251:947-950.
39. Shekhar A., Potter W.Z., Lightfoot J., Lienemann J., Dubé S., Mallinckrodt C., Bymaster F.P., McKinzie D.L., Felder C.C. Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am. J. Psychiatry 2008, 165:1033-1039.
40. 2A receptor inverse agonist. J. Pharmacol. Exp. Ther. 2010, 332:622-631.
41. Sur C., Mallorga P.J., Wittmann M., Jacobson M.A., Pascarella D., Williams J.B., Brandish P.E., Pettibone D.J., Scolnick E.M., Conn P.J. N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-d-aspartate receptor activity. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:13674-13679.
42. Tollefson G.D. Cognitive function in schizophrenic patients. J. Clin. Psychiatry 1996, 57:31-39.
43. 2A receptor inverse agonist. J. Pharmacol. Exp. Ther. 2006, 317:910-918.
44. Volavka J., Czobor P., Sheitman B., Lindenmayer J.P., Citrome L., McEvoy J.P., Cooper T.B., Chakos M., Lieberman J.A. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am. J. Psychiatry 2002, 159:255-262.
45. Weigmann H., Härtter S., Fischer V., Dahmen N., Hiemke C. Distribution of clozapine and desmethylclozapine between blood and brain in rats. Eur. Neuropsychopharmacol. 1999, 9:253-256.
46. Weinberger D.R., Berman K.F., Suddath R., Torrey E.F. Evidence of dysfunction of a prefrontal-limbic network in schizophrenia: a magnetic resonance imaging and regional cerebral blood flow study of discordant monozygotic twins. Am. J. Psychiatry 1992, 149:890-897.
47. Weiner D.M., Meltzer H.Y., Veinbergs I., Donohue E.M., Spalding T.A., Smith T.T., Mohell N., Harvey S.C., Lameh J., Nash N., Vanover K.E., Olsson R., Jayathilake K., Lee M., Levey A.I., Hacksell U., Burstein E.S., Davis R.E., Brann M.R. The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine. Psychopharmacology 2004, 177:207-216.
48. Winters B.D., Bussey T.J. Transient inactivation of perirhinal cortex disrupts encoding, retrieval, and consolidation of object recognition memory. J. Neurosci. 2005, 25:52-61.
49. Wolff M.C., Leander J.D. Comparison of the effects of antipsychotics on a delayed radial maze task in the rat. Psychopharmacology 2003, 168:410-416.
50. 6 receptor antagonist, Ro 04-6790. Psychopharmacology 2003, 170:358-367.